Blood cancers

Ixazomib a valuable maintenance option in newly-diagnosed MM

Ixazomib is a novel induction-agnostic maintenance option for transplantation-ineligible patients with newly diagnosed multiple myeloma, a study suggests. The drug is a second generation proteasome inhibitor (PI) and the only one that can be taken orally. And according to results from the phase III TOURMALINE-MM4 trial, it significantly lowered the risk of disease progression compared ...

Already a member?

Login to keep reading.

© 2021 the limbic